US 11242525
CRISPR/CAS-related methods and compositions for treating sickle cell disease
granted A61KA61K48/005A61P
Quick answer
US patent 11242525 (CRISPR/CAS-related methods and compositions for treating sickle cell disease) held by Editas Medicine, Inc. expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K48/005, A61P, A61P7/06